Indications and uses
Uses : Temporary relief of cold and flu symptoms, such as: fever, headache, minor aches and pains.
Uses : Temporary relief of cold and flu symptoms, such as: fever, headache, minor aches and pains.
Take on an empty stomach. Adults and children 12 years and older Take 1 tube contents to be dissolved in the mouth, every 6 hours, up to 3 times per day. Children between 12 years and 6 years of age. Take 1 tube contents to be dissolved into a little water, every 6 hours, up to 3 times per day. Children under 6 years Consult a physician.
ACONITUM NAPELLUS 5C FEVER
ANAS BARBARIAE 200CK FLU-LIKE SYMPTOMS DUE TO BACTERIAL INFECTIONS
ASCLEPIAS VINCETOXICUM 5C FEVER DUE TO VIRAL INFECTIONS
BELLADONNA 5C FEVER
CUPRUM METALLICUM 3C HEADACHE, MUSCLE PAIN
ECHINACEA ANGUSTIFOLIA 3C IMMUNE SUPPORT
HAEMOPHILUS INFLUENZAE 9C FLU-LIKE SYMPTOMS DUE TO BACTERIAL INFECTIONS
If pregnant or breast-feeding ask a health professional before use.
Take on an empty stomach.
Adults and children 12 years and older Take 1 tube contents to be dissolved in the mouth, every 6 hours, up to 3 times per day.
Children between 12 years and 6 years of age. Take 1 tube contents to be dissolved into a little water, every 6 hours, up to 3 times per day.
Children under 6 years Consult a physician.
Questions?: info@gunainc.com
tel. (484) 223-3500
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| c599c4a0-705d-4ebb-ab1f-977af038f96a | Product name | 1 | 20251124 |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 17089-025-17 | GUNA-FLU | 6 in 1 BOX | PELLET | 6 | 7 | |
| 17089-025-17 | GUNA-FLU | 1 g in 1 TUBE | PELLET | 1 | 7 |
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 17089-025 | GUNA-FLU (ACONITUM NAPELLUS - ASCLEPIAS CURASSAVICA - ATROPA BELLADONNA - CAIRINA MOSCHATA HEART/LIVER AUTOLYSATE - COPPER - ECHINACEA ANGUSTIFOLIA - HAEMOPHILUS INFLUENZAE TYPE B -) PELLET [GUNA SPA] | 7 | Current NDC, Legacy NDC, 2 package rows | 20221115_84e8e18c-8a74-41d5-b285-1ecb788bba3d.zip |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| ACONITUM NAPELLUS | ACTIVE INGREDIENT | U0NQ8555JD | 4 | |
| ASCLEPIAS CURASSAVICA | ACTIVE INGREDIENT | JSZ93E47EP | 4 | |
| ATROPA BELLADONNA | ACTIVE INGREDIENT | WQZ3G9PF0H | 4 | |
| CAIRINA MOSCHATA HEART/LIVER AUTOLYSATE | ACTIVE INGREDIENT | RN2HC612GY | 4 | |
| COPPER | ACTIVE INGREDIENT | 789U1901C5 | 4 | |
| ECHINACEA ANGUSTIFOLIA | ACTIVE INGREDIENT | VB06AV5US8 | 4 | |
| HAEMOPHILUS INFLUENZAE TYPE B | ACTIVE INGREDIENT | F2TW0N64FI | 4 | |
| ACONITUM NAPELLUS | ACTIVE MOIETY | U0NQ8555JD | 4 | |
| ASCLEPIAS CURASSAVICA | ACTIVE MOIETY | JSZ93E47EP | 4 | |
| ATROPA BELLADONNA | ACTIVE MOIETY | WQZ3G9PF0H | 4 | |
| CAIRINA MOSCHATA HEART/LIVER AUTOLYSATE | ACTIVE MOIETY | RN2HC612GY | 4 | |
| COPPER | ACTIVE MOIETY | 789U1901C5 | 4 | |
| ECHINACEA ANGUSTIFOLIA | ACTIVE MOIETY | VB06AV5US8 | 4 | |
| HAEMOPHILUS INFLUENZAE TYPE B | ACTIVE MOIETY | F2TW0N64FI | 4 | |
| SUCROSE | INACTIVE INGREDIENT | C151H8M554 | 4 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 17089-025 | 17089-025-17 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| SUCROSE | C151H8M554 | IACT |
| ACONITUM NAPELLUS | U0NQ8555JD | ACTIB |
| CAIRINA MOSCHATA HEART/LIVER AUTOLYSATE | RN2HC612GY | ACTIB |
| ASCLEPIAS CURASSAVICA | JSZ93E47EP | ACTIB |
| ATROPA BELLADONNA | WQZ3G9PF0H | ACTIB |
| COPPER | 789U1901C5 | ACTIB |
| ECHINACEA ANGUSTIFOLIA | VB06AV5US8 | ACTIB |
| HAEMOPHILUS INFLUENZAE TYPE B | F2TW0N64FI | ACTIB |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| SUCROSE | SUCROSE | C151H8M554 | GRANULE, FOR SUSPENSION / ORAL | 31885 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, COATED, EXTENDED RELEASE / ORAL | 86 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, FILM COATED / ORAL | 145 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, DELAYED RELEASE / ORAL | 295.33 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | PASTILLE / ORAL | 426 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SOLUTION / ORAL | 70000 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, DELAYED RELEASE / ORAL | 955 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CONCENTRATE / ORAL | 4800 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, COATED / ORAL | 516.42 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE / ORAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE, FOR SOLUTION / ORAL | 42596 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 119.12 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, FILM COATED / ORAL | 145 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SUSPENSION / ORAL | 48209 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, DELAYED RELEASE / ORAL | 955 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, EXTENDED RELEASE / ORAL | 619 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SUSPENSION/ DROPS / ORAL | 3750 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TROCHE / ORAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | LIQUID / ORAL | 37500 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | POWDER, FOR SUSPENSION / ORAL | 40017 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, CHEWABLE / ORAL | 7258 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 119.12 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, COATED PELLETS / ORAL | 59.8 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SUSPENSION, EXTENDED RELEASE / ORAL | 5400 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | POWDER, FOR SOLUTION / ORAL | 38666 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, EXTENDED RELEASE / ORAL | 284.54 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | POWDER / ORAL | 27768 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CONCENTRATE / ORAL | 4800 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | PASTILLE / ORAL | 426 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE, FOR SOLUTION / ORAL | 42596 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, CHEWABLE / ORAL | 7258 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | POWDER, FOR SOLUTION / ORAL | 38666 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | POWDER, FOR SUSPENSION / ORAL | 40017 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET / ORAL | 4249 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | ELIXIR / ORAL | 18000 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | DROPS / ORAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | SUSPENSION, EXTENDED RELEASE / ORAL | 5400 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | ELIXIR / ORAL | 18000 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TROCHE / ORAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, COATED, EXTENDED RELEASE / ORAL | 86 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | LIQUID / ORAL | 37500 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE / ORAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | WAFER / ORAL | 155.2 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | DROPS / ORAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE / ORAL | 3568 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET / ORAL | 4249 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SYRUP / ORAL | 46400 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE, FOR SUSPENSION, EXTENDED RELEASE / ORAL | 18790 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SUSPENSION / ORAL | 48209 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, EXTENDED RELEASE / ORAL | 284.54 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, COATED / ORAL | 516.42 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, DELAYED RELEASE / ORAL | 295.33 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SYRUP / ORAL | 46400 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE, FOR SUSPENSION, EXTENDED RELEASE / ORAL | 18790 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, EXTENDED RELEASE / ORAL | 619 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE, FOR SUSPENSION / ORAL | 31885 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SUSPENSION/ DROPS / ORAL | 3750 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE / ORAL | 3568 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SOLUTION / ORAL | 70000 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | WAFER / ORAL | 155.2 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| GUNA-FLU | ACONITUM NAPELLUS - ASCLEPIAS CURASSAVICA - ATROPA BELLADONNA - CAIRINA MOSCHATA HEART/LIVER AUTOLYSATE - COPPER - ECHINACEA ANGUSTIFOLIA - HAEMOPHILUS INFLUENZAE TYPE B - | Guna spa | 84e8e18c-8a74-41d5-b285-1ecb788bba3d | 2022-11-14 | Warnings | 17089-025-17 17089-025 17089002517 92ac92a1-762e-5c83-e053-2995a90a3350 84e8e18c-8a74-41d5-b285-1ecb788bba3d |
Adverse event summaries are temporarily unavailable. Other product information remains available.